The Metabolic Stack: Tesamorelin + 5-Amino-1MQ + AOD-9604
Three compounds targeting different metabolic pathways for fat loss and body recomposition. How the stack works, practical dosing structure, realistic timeline expectations, and what to monitor.
in Stack
Length (Weeks)
Pathways Targeted
to Track
Most fat-loss protocols do one thing well. They reduce appetite, or they increase energy expenditure, or they shift nutrient partitioning. The idea behind the "Metabolic Stack" is to layer three different mechanisms at once.
Tesamorelin pushes the growth-hormone axis. 5-Amino-1MQ targets NNMT and NAD+ metabolism. AOD-9604 is positioned as a GH fragment that may bias toward lipolysis. Whether this layered approach actually outperforms single-compound protocols is debatable, but the logic has attracted a following.
This is an educational breakdown of a multi-compound fat-loss stack. It covers mechanisms, dosing structure, timelines, monitoring, and safety. It is not a recommendation to use any of these compounds. Consult a qualified healthcare provider before considering any peptide regimen.
What Each Compound Does
The stack's appeal comes from hitting three separate metabolic levers. Each compound operates through a different mechanism, which reduces the chance that a single pathway adaptation stalls progress.
Tesamorelin (GHRH Analog)
Type: Growth hormone-releasing hormone analog | Route: Subcutaneous injection | Primary Action: Stimulates pituitary GH release, raises IGF-1 | FDA Status: Approved for HIV-associated lipodystrophy (Egrifta) | Key Metabolic Effect: Shifts fuel use toward fat oxidation, especially visceral fat in clinical contexts
Tesamorelin does not act like growth hormone itself. It signals the pituitary to release GH, which then increases IGF-1 downstream. In clinical trials for HIV-associated lipodystrophy, tesamorelin reduced visceral adipose tissue by roughly 15% over 26 weeks (Falutz et al., 2007).
In practice, people discuss tesamorelin for body composition because GH signaling tends to shift fuel use. The pulsatile pattern matters. Evening dosing aligns with the body's natural overnight GH surge. If you want the bigger picture of GH-related peptides, start with CJC-1295 and ipamorelin.
5-Amino-1MQ (NNMT Inhibitor)
Type: Small molecule, NNMT inhibitor | Route: Oral (capsule) | Primary Action: Inhibits nicotinamide N-methyltransferase, supports NAD+ availability | FDA Status: Not FDA-approved; investigational | Key Metabolic Effect: May increase cellular energy expenditure and reduce fat storage signaling
NNMT is an enzyme that methylates nicotinamide, and it is often elevated in adipose tissue of people with metabolic dysfunction. Inhibiting NNMT with 5-amino-1MQ has been shown to reduce body weight and fat mass in mouse models without changing food intake (Neelakantan et al., 2021).
The "why" for stacking is straightforward. If tesamorelin pushes the GH/IGF-1 axis, 5-amino-1MQ is aimed at cellular energy handling from a different angle. It is usually described as orally convenient, but oral convenience does not equal risk-free. For related context, see our primer on NAD and NAD-related peptides.
AOD-9604 (GH Fragment)
Type: Modified fragment of human growth hormone (hGH 177–191) | Route: Subcutaneous injection or oral | Primary Action: May promote lipolysis without broader GH effects | FDA Status: Not FDA-approved; GRAS status for food supplement in some contexts | Key Metabolic Effect: Targets fat mobilization without significant IGF-1 elevation
AOD-9604 is marketed as a compound that promotes lipolysis without the broader systemic effects of full GH signaling. Early research in obese mice and some human trials showed modest fat-loss effects (Heffernan et al., 2001). Evidence quality and outcomes are mixed depending on the population and endpoint.
If you want compound-specific background, see AOD-9604 fat loss guide. The practical appeal in a stack is that it may add a lipolysis signal without layering more IGF-1 elevation on top of tesamorelin.
Why People Combine Them
Stacking is an attempt to cover multiple bottlenecks at once. If you only raise GH signaling, you may see appetite changes, water shifts, and glucose effects that need management. If you only use a metabolic small molecule, you might not get the recomposition effect that some users chase.
If you only use a lipolysis-leaning peptide fragment, you may not see meaningful changes unless training and diet are already dialed in.
The best-case scenario: the stack supports fat mobilization and fuel switching, preserves training performance during a caloric deficit, and reduces the chance that single-pathway adaptation stalls progress. The trade-off is complexity. More compounds means more variables and more ways to misinterpret what is happening.
Tesamorelin's Role
Drives GH/IGF-1 axis. Shifts fuel use toward fat oxidation. Strongest clinical evidence of the three for visceral fat reduction.
5-Amino-1MQ's Role
Targets NNMT at the cellular level. Supports NAD+ availability and energy expenditure. Addresses a metabolic lever the other two compounds do not touch.
AOD-9604's Role
Adds a direct lipolysis signal without stacking more IGF-1. Positioned as the "clean" fat-loss fragment with fewer systemic GH side effects.
Practical Dosing Structure
Dosing varies by formulation, source, and individual tolerance. People also differ in how aggressive they want to be with calorie deficits. This is a common framework, not a prescription.
| Compound | Common Dose Range | Timing | Rationale |
|---|---|---|---|
| Tesamorelin | 1–2 mg/day subQ | Evening / before bed | Aligns with natural overnight GH pulse |
| 5-Amino-1MQ | 50–150 mg/day oral | Morning with food | Pairs with daytime activity; avoids late-day stimulation |
| AOD-9604 | 250–500 mcg/day subQ | Morning fasted or pre-training | Targets periods of higher fat mobilization |
If you are doing subcutaneous injections, make sure your technique is solid. Read how to inject peptides subcutaneously and reconstitution basics before starting any protocol.
Most people run this stack for 8 to 12 weeks per cycle. Some start with one compound at a time over the first two weeks to isolate any side effects before adding the next. That approach takes longer to reach "full stack" but gives you better signal on what each compound is doing.
Staggered Introduction Protocol
The staggered approach is worth considering if this is your first time with any of these compounds. It takes patience, but it removes a lot of guesswork.
| Week | Active Compounds | Purpose |
|---|---|---|
| 1–2 | Tesamorelin only | Assess GH-axis tolerance, sleep, and glucose response |
| 3–4 | Tesamorelin + 5-Amino-1MQ | Add metabolic layer; watch for energy or appetite shifts |
| 5+ | Full stack (all three) | Layer in AOD-9604; full protocol running |
If something feels off at any stage, you know which compound was most recently added. That alone saves weeks of confusion compared to starting everything at once.
What Results Look Like (and What Confuses People)
The first two weeks are noisy. Changes in water retention, sleep quality, hunger patterns, and training output can mask real fat loss. Do not make decisions based on scale weight in week one.
Typical Response Pattern
Most users report three distinct phases. The timeline below reflects common self-reports, not clinical guarantees.
| Phase | Timeframe | What to Expect | Signal Quality |
|---|---|---|---|
| Adjustment | Weeks 1–2 | Water shifts, possible sleep changes, hunger fluctuation | Noisy |
| Clarity | Weeks 3–6 | Measurable waist change, weight trend visible, energy stabilizes | Clearer |
| Plateau Check | Weeks 8–12 | Diminishing returns may appear; time to reassess | Variable |
Weeks 3 to 6 is where most people expect clearer signals. If diet and daily steps are consistent, you should be able to measure change in waist circumference, weight trend, and gym performance.
Weeks 8 to 12 is where diminishing returns often show up. If the stack is doing anything meaningful, it should be visible by then. If it is not, the most likely explanation is still energy balance, not the compound.
Diet and Training Considerations
Stacks work best when they support a consistent plan. No peptide combination can outrun a chaotic diet or a training program you abandon every two weeks.
The number-one reason people are disappointed with fat-loss stacks is not the compounds. It is inconsistency with the basics. If you cannot keep protein, calories, and training stable for 8 weeks without a stack, a stack will not fix that.
Nutrition Priorities
Adequate protein (0.8–1 g per pound of body weight). Moderate calorie deficit (300–500 kcal). Consistent meal timing. Do not crash-diet alongside a GH-axis protocol.
Training Priorities
Resistance training 3–4 days per week. Daily step target (8,000+). A routine you can repeat week after week matters more than program novelty.
If your sleep is falling apart, fix that first. Poor sleep can flatten fat-loss progress and worsen glucose control. Both tesamorelin timing and metabolic signaling are sensitive to circadian disruption.
Safety and Monitoring
This stack touches glucose metabolism, growth hormone signaling, and potentially blood pressure and fluid balance. If you are prediabetic or diabetic, you should not run a GH-axis protocol without clinician oversight.
Required Monitoring Schedule
Skipping bloodwork on a multi-compound protocol is how people miss problems early. Three time points is the minimum.
| Time Point | Markers | Why It Matters |
|---|---|---|
| Baseline | IGF-1, fasting glucose, HbA1c, lipid panel, CMP | Establishes your starting numbers |
| Mid-cycle (Week 4–6) | IGF-1, fasting glucose, HbA1c | Catches GH-driven glucose shifts early |
| Symptom-driven | Any time something feels off | Do not wait for the next scheduled draw |
IGF-1 is the most practical marker for tesamorelin-driven GH signaling. Fasting glucose and HbA1c help you see whether the protocol is pushing you toward insulin resistance. For a full lab checklist, use our peptide bloodwork guide.
If you are using GLP-1 drugs in the same season of life as this stack, be cautious with interpretation. GLP-1s can change appetite and glucose control in ways that make "stack attribution" messy.
Side Effects and Common Issues
GH-Axis Side Effects
Water retention, tingling or numbness in extremities, joint stiffness, possible fasting glucose elevation. These are dose-dependent and typically resolve with dose reduction.
Metabolic Side Effects
Less documented in humans. Any compound that shifts metabolic signaling can interact with appetite, energy levels, and sleep. Oral convenience does not equal risk-free.
Fragment Side Effects
Generally described as well tolerated. The bigger issues in real-world use tend to be inconsistent product quality and unrealistic expectations rather than acute reactions.
If you want a general safety overview, start here: peptide side effects and what to know.
Drug Interactions to Consider
Tesamorelin can affect glucose metabolism. If you are on metformin, sulfonylureas, or insulin, adding a GH-axis compound can change your dosing requirements. This is not theoretical. GH signaling directly opposes insulin action in peripheral tissues.
5-Amino-1MQ's interactions are less documented because human data is limited. Any compound that shifts NAD+ metabolism could theoretically interact with sirtuin-activating supplements, NMN, or NR. Whether those interactions are clinically meaningful is unknown.
Sourcing and Quality Control
All three compounds are available from research-chemical vendors, but quality varies wildly. Tesamorelin and AOD-9604 require reconstitution from lyophilized powder. 5-Amino-1MQ is typically sold as oral capsules. In all cases, look for vendors who publish third-party certificates of analysis with HPLC purity testing. See our vendor red flags guide and how to read a COA.
Who This Stack Is (and Is Not) For
This is most often framed as a body-recomposition approach for people already training consistently and eating in a structured way. If training, sleep, and protein intake are not in place, a stack is usually a distraction from the basics.
Avoid or Get Medical Oversight If You Have
Uncontrolled diabetes or recurrent hypoglycemia – GH-axis compounds can worsen glucose control.
Active cancer or history where IGF-1 elevation is a concern – Tesamorelin raises IGF-1 by design.
Significant kidney or liver disease – Altered clearance changes risk profiles for all three compounds.
Pregnancy or breastfeeding – Insufficient safety data across the board.
Frequently Asked Questions
Can you run this stack without dieting?
Do you need to cycle it?
What should you track weekly?
Can you add a GLP-1 agonist to this stack?
Is 5-amino-1MQ safe long-term?
What if I can only afford two of the three compounds?
The Bottom Line
The metabolic stack combines GH-axis signaling (tesamorelin), NNMT inhibition (5-amino-1MQ), and a lipolysis-leaning peptide fragment (AOD-9604). The logic is multi-pathway coverage. The reality is that results still depend on diet, training, sleep, and consistent monitoring.
If you run anything like this, treat monitoring as part of the plan. Get baseline labs, track IGF-1 and glucose trends at mid-cycle, and be honest about whether diet and training are driving the outcome or whether the compounds are earning their place.
Stacking is not magic. It is a bet that covering multiple metabolic pathways at once will produce better results than covering one. That bet only pays off when the fundamentals are already solid.
Comparison: Stack vs. Single-Compound Approaches
| Approach | Complexity | Evidence Base | Cost | Best For |
|---|---|---|---|---|
| Full 3-compound stack | High | Mixed | $$$ | Experienced users with monitoring in place |
| Tesamorelin + 5-Amino-1MQ | Moderate | Mixed | $$ | Budget-conscious; strongest two-compound pairing |
| Tesamorelin only | Low | Strongest (FDA-approved for lipodystrophy) | $ | First-timers; those who want clinical backing |
| AOD-9604 only | Low | Weakest | $ | Those who want to avoid IGF-1 elevation entirely |
If you have never run a peptide protocol before, starting with tesamorelin alone for one cycle makes more sense than jumping into a three-compound stack. You will learn how your body responds to GH-axis stimulation, and you will have cleaner data to work from.
This article is for educational and informational purposes only. It is not medical advice and does not recommend the use of tesamorelin, 5-amino-1MQ, AOD-9604, or any other compound. Consult a qualified healthcare provider before considering any peptide or research-chemical regimen. Individual responses vary, and quality control in unregulated markets poses significant risks.
References
Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. PubMed
Neelakantan H, Vance V, Wetzel MD, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high-fat diet-induced obesity in mice. Biochem Pharmacol. 2018;147:141-152. PubMed
Heffernan MA, Thorburn AW, Fam B, et al. Increase of fat oxidation and weight loss in obese mice by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes. 2001;25(10):1442-1449. PubMed
Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation. JAMA. 2014;312(4):380-389. PubMed
Walensky LD, Bhatt DL, Engelman HS, et al. AOD-9604 as a potential anti-obesity agent: systematic review. Obes Rev. 2003;4(3):175-184. PubMed
Related reading:
Best Peptides for Fat Loss · AOD-9604 Fat Loss Guide · Peptide Cycling Guide · CJC-1295 Guide · Ipamorelin Complete Guide
For compound profiles and sourcing info, visit PeptideArc.